INDIANAPOLIS–In a deal worth at least $720 million, Eli Lilly and Company says it will supply the U.S. government up to 600,000 thousand doses of a drug for the treatment of mild to moderate COVID-19 in certain high-risk patients.
The agreement is conditional on Lilly getting Emergency Use Authorization for the drug, which is called bebtelovimab. That request has been submitted to the FDA.
The deal also provides for an option of 500,000 additional doses.
Bebtelovimab can be used to treat people 12 and older who have mild to moderate COVID-19 and are at high risk of a severe form of the disease or for whom other treatment options aren’t accessible or clinically appropriate. It is not authorized for hospitalized patients or those who need oxygen therapy.
